First Time Loading...

Elanco Animal Health Inc
NYSE:ELAN

Watchlist Manager
Elanco Animal Health Inc Logo
Elanco Animal Health Inc
NYSE:ELAN
Watchlist
Price: 13.585 USD 2.45%
Updated: May 7, 2024
Section:
 

Relative Value

The Relative Value of one ELAN stock under the Base Case scenario is 29.155 USD. Compared to the current market price of 13.585 USD, Elanco Animal Health Inc is Undervalued by 53%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ELAN Relative Value
Base Case
29.155 USD
Undervaluation 53%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
74
vs Industry
62
Median 3Y
1.7
Median 5Y
2.8
Industry
2.5
Forward
1.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-28.3
Median 5Y
-25.6
Industry
23.4
Forward
14.1
More Details
24.7
P/OCF
P/OCF
Price to OCF
24.7
vs History
63
vs Industry
20
Median 3Y
24.5
Median 5Y
27.8
Industry
17.4
More Details
167.4
P/FCFE
P/FCFE
Price to FCFE
167.4
vs History
15
vs Industry
4
Median 3Y
29.6
Median 5Y
4.2
Industry
23.6
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
71
vs Industry
60
Median 3Y
1.2
Median 5Y
1.6
Industry
2.1
More Details
2.7
EV/S
EV/S
Enterprise Value to Sales
2.7
vs History
74
vs Industry
43
Median 3Y
2.9
Median 5Y
3.7
Industry
2.6
Forward
2.6
More Details
4.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.8
vs History
73
vs Industry
44
Median 3Y
5.1
Median 5Y
6.8
Industry
5.2
More Details
11.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.7
vs History
71
vs Industry
31
Median 3Y
12.5
Median 5Y
16.9
Industry
13.7
Forward
11.3
More Details
36.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
36.6
vs History
42
vs Industry
12
Median 3Y
36.4
Median 5Y
35.7
Industry
17.2
Forward
14.6
More Details
44
EV/OCF
EV/OCF
Enterprise Value to OCF
44
vs History
39
vs Industry
9
Median 3Y
39
Median 5Y
39.5
Industry
16.2
More Details
101.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
101.9
vs History
20
vs Industry
6
Median 3Y
38.2
Median 5Y
43.9
Industry
17.8
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
73
vs Industry
63
Median 3Y
0.9
Median 5Y
1.2
Industry
2
More Details

Multiples Across Competitors

ELAN Competitors Multiples
Elanco Animal Health Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Elanco Animal Health Inc
NYSE:ELAN
6.5B USD 1.5 -5.4 11.7 36.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
735.4B USD 20.5 119.5 58.7 66.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.9 46.8 34.2 37.3
US
Johnson & Johnson
NYSE:JNJ
359.1B USD 4.2 9.3 11.5 15
US
Merck & Co Inc
NYSE:MRK
326B USD 5.3 141.3 35.2 57.5
UK
AstraZeneca PLC
LSE:AZN
187.8B GBP 5 37.2 174.3 278.1
CH
Novartis AG
SIX:NOVN
183B CHF 4.3 13.6 9.9 16.4
CH
Roche Holding AG
SIX:ROG
176.4B CHF 3 15.3 8.7 10.4
US
Pfizer Inc
NYSE:PFE
159.8B USD 2.9 -516.7 12.8 20.4
P/E Multiple
Earnings Growth
US
Elanco Animal Health Inc
NYSE:ELAN
Average P/E: 54.7
Negative Multiple: -5.4 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.5
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
46.8
84%
US
Johnson & Johnson
NYSE:JNJ
9.3
-20%
US
Merck & Co Inc
NYSE:MRK
141.3
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.2
168%
CH
Novartis AG
SIX:NOVN
13.6
15%
CH
Roche Holding AG
SIX:ROG
15.3
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -516.7
680%

See Also

Summary
ELAN intrinsic value, competitors valuation, and company profile.
DCF Valuation
ELAN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ELAN stock valuation using valuation multiples.
Wall Street Estimates
ELAN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ELAN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.